Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study will test the effect of four common oral anti-diabetic agents on hepatic insulin
sensitivity in South Asian women with impaired glucose tolerance or impaired fasting glucose.
In a 12-week, double-blind, randomized controlled intervention trial, the following drugs
will be tested head-to-head: Metformin, Pioglitazone, Empagliflozin and Linagliptin.
Additional, exploratory outcomes include whole body insulin sensitivity, insulin secretion
and other markers of glucose and lipid metabolism, measured by the euglycemic clamp with
stable isotope tracer dilution, indirect calorimetry and CT-measurements of abdominal adipose
tissue compartment volumes and hepatic and pancreatic volume and attenuation.
The study is part of the DIASA - DIAbetes in South Asians - Research Programme, which aims to
find ways to improve both prevention and treatment of type 2 diabetes in people of South
Asian ethnicity.
Phase:
Phase 2
Details
Lead Sponsor:
Oslo University Hospital
Collaborators:
Norwegian Diabetes Association South-Eastern Norway Regional Health Authority The Research Council of Norway University Hospital, Akershus University of Glasgow University of Oslo Vestre Viken Hospital Trust